Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Brain Cancer Market Overview at a Glance
4.1 Market Share by Therapies (%) Distribution of Brain Cancer in 2023 (Global Overview)
4.2 Market Share by Therapies (%) Distribution of Brain Cancer in 2032 (Global Overview)
5. Key Events
6. Epidemiology and Market Forecast Methodology
7. Disease Background and Overview
7.1 Introduction
7.2 Types of Brain Cancer
7.2.1 Primary Brain Tumors
7.2.2 Secondary Brain Tumors
7.3 Symptoms
7.4 Causes and Risk Factors
7.5 Prevention
7.6 Brain Tumor Grading
7.7 Clinical Presentation
7.8 Biomarkers
7.9 Diagnosis
7.9.1 Neurological Examination
7.9.2 Imaging Tests
7.9.3 Lumbar Puncture or Spinal Tap
7.9.4 Advanced Genomic Testing
7.9.5 Nuclear Medicine Bone Scan
7.9.6 Angiography
7.9.7 Electroencephalography (EEG)
7.9.8 Evoked Potentials
7.9.9 Brain Biopsy
7.10 Diagnostic Guidelines for Adult Astrocytic and Oligodendroglial Gliomas
8. Treatment Landscape
8.1 Radiation Therapy
8.2 Surgery
8.3 Chemotherapy
8.4 Targeted Therapy
8.5 Laser Thermal Ablation
8.6 Alternating Electric Field Therapy
8.7 Other Drug Treatments
8.8 Treatment of Brain Tumors by Type
8.8.1 Non-Infiltrating Astrocytomas
8.8.2 Low-Grade Infiltrating Astrocytomas
8.8.3 Intermediate-Grade Gliomas
8.8.4 Oligodendrogliomas
8.8.5 Ependymomas
8.8.6 Meningiomas
8.8.7 Schwannomas
8.9 National Comprehensive Cancer Network (NCCN) Guidelines for Brain Cancer
8.10 Neurological and Vascular Complications of Brain Tumors
9. Treatment Algorithm
10. Epidemiology and Patient Population
10.1 Key Findings
10.2 Assumptions and Rationale
10.3 Total Incidence of Primary Brain Tumors (Global Overview)
10.4 Regional Breakdown:
10.4.1 North America
10.4.2 Europe
10.4.3 APAC
10.4.4 MEA
10.4.5 South America
11. Patient Journey
12. Marketed Drugs
12.1 Key Competitors
12.2 Drug Profiles (Example Drugs):
12.2.1 AVASTIN (Genentech)
12.2.2 TEMODAR (Merck)
12.2.3 GLIADEL Wafer (Arbor Pharmaceuticals)
13. Emerging Therapies
13.1 Key Competitors
13.2 Emerging Drug Profiles (Example Therapies):
13.2.1 Paxalisib (Kazia Therapeutics)
13.2.2 Vorasidenib (Servier)
14. Brain Cancer Global Market Analysis
14.1 Key Findings
14.2 Market Outlook (2024–2032)
14.3 Region-Wise Market Forecast (North America, Europe, APAC, MEA, South America)
14.4 Market Share by Therapy (Global)
15. Unmet Needs
16. SWOT Analysis
17. Key Opinion Leader (KOL) Views
18. Reimbursement and Market Access
18.1 North America
18.2 Europe
18.3 APAC, MEA, and South America
19. Appendix
19.1 Bibliography
19.2 Report Methodology
20. Disease Root Analysis Capabilities
21. Disclaimer
22. About Disease Root Analysis